APA (7th ed.) Citation

Kalunian, K. C., Furie, R., Morand, E. F., Bruce, I. N., Manzi, S., Tanaka, Y., . . . Al‐Mossawi, H. (2023). A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & Rheumatology, 75(2), 253-265. https://doi.org/10.1002/art.42392

Chicago Style (17th ed.) Citation

Kalunian, Kenneth C., et al. "A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus." Arthritis & Rheumatology 75, no. 2 (2023): 253-265. https://doi.org/10.1002/art.42392.

MLA (9th ed.) Citation

Kalunian, Kenneth C., et al. "A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus." Arthritis & Rheumatology, vol. 75, no. 2, 2023, pp. 253-265, https://doi.org/10.1002/art.42392.